Premium
Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance
Author(s) -
Koomägi Reet,
Volm Manfred
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990621)84:3<239::aid-ijc7>3.0.co;2-s
Subject(s) - fas receptor , fas ligand , lung cancer , relevance (law) , clinical significance , oncology , cancer research , medicine , ligand (biochemistry) , predictive value , predictive marker , pathology , cancer , biology , apoptosis , receptor , genetics , programmed cell death , political science , law
In order to examine whether or not the expression of the apoptosis‐related receptor Fas (CD‐95/APO‐1) and its ligand (FasL) has relevance for patient survival, immunohistochemistry was used to analyze the proteins of both factors in 164 non‐small cell lung carcinomas. Patients with Fas‐positive tumors exhibited significantly longer survival times than patients with Fas‐negative carcinomas. In contrast, FasL did not significantly influence patient survival time. A multivariate analysis of clinical and biological factors indicated that lymph node status and Fas expression were significant prognostic factors. Carcinoma patients who were negative for both Fas and FasL had a significantly higher incidence of lymph node involvement than did carcinoma patients who were positive for Fas and FasL. Carcinomas that were positive for Fas and FasL demonstrated a greater sensitivity to doxorubicin in vitro . Int. J. Cancer (Pred. Oncol.) 84:239–243, 1999. © 1999 Wiley‐Liss, Inc.